Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

5.195 -0.215 (-3.97%)
Streaming Delayed Price Updated: 10:32 AM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Why Infosys Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers PainReform Ltd. (NASDAQ: PRFX) jumped 45.5% to $10.34 after declining 8% on Wednesday. PaiReform recently regained compliance with Nasdaq continued listing requirements. 
Via Benzinga
Dow On Track For 9 Straight After Johnson & Johnson Earnings
The Dow Jones Industrial Average is looking to extend its win streak, last seen up 250 points as it paces for its ninth consecutive win. 
Via Talk Markets
Dow Surges 300 Points; Johnson & Johnson Posts Upbeat Earnings
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite declining over 1% on Thursday. The Dow traded up 0.87% to 35,365.00 while the NASDAQ fell 1.11% to 14,198.86. The S&P 500,... 
Via Benzinga
Why Vir Biotechnology Stock Is Plunging Today?
Vir Biotechnology Inc (NASDAQ: VIR) shares are tumbling after the company released data from the Phase 2 PENINSULA evaluating VIR-2482 to prevent  
Via Benzinga
What 8 Analyst Ratings Have To Say About Vir Biotechnology
Via Benzinga
Why Shares of Vir Biotechnology Are Plunging Thursday
The company had disappointing trial news for one of its lead therapies. 
Via The Motley Fool
Nasdaq Down 50 Points; Tesla Earnings Beat Expectations
U.S. stocks traded mixed this morning, with the Dow Jones gaining over 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.40% to 35,202.41 while the NASDAQ fell 0.35% to... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer
From Vir Biotechnology, Inc.
Via GlobeNewswire
Post-COVID-19: How the COVAX Initiative Could Redirect its $2.6B Surplus to Fight Future Pandemics
As the emergency phase of the COVID-19 pandemic draws to a close, the COVAX initiative, run by Gavi, the WHO, and CEPI, reportedly has $2.6 billion left over that could be used to prepare for other... 
Via Benzinga
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023
– Data support the potential impact of VIR-2218 and VIR-3434 in addressing both HBV and HDV and underscore the Company’s confidence in its approach to a functional cure for HBV – 
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
From Vir Biotechnology, Inc.
Via GlobeNewswire
WHO Recommends New COVID Booster Shots To Target XBB Variants, Despite Slower Uptake
An advisory group for the World Health Organization said the current crop of shots should be updated to target the currently dominant XBB strains for the 
Via Benzinga
Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI
From Vir Biotechnology, Inc.
Via GlobeNewswire
7 Top-Rated Stocks That Will Boost Your Portfolio in 2023
For those seeking to rise above the muck in a big way, these top-rated stocks to buy might accomplish just that. 
Via InvestorPlace
WHO Ends Global Emergency Status for COVID-19 3 Years After Declaration, CDC Director Resigns
The World Health Organization ended the global emergency 
Via Benzinga
The 7 Best Bargain Stocks to Buy for May 2023
With inflation crimping everyone’s wallet, these best bargain stocks to buy can make your dollars stretch significantly. 
Via InvestorPlace
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention
From Vir Biotechnology, Inc.
Via GlobeNewswire
Why Shares of Keros Therapeutics Jumped This Week
The company appointed a new director and an analyst reiterated his position on the stock. 
Via The Motley Fool
Vir Biotechnology to Participate in the 22nd Annual Needham Virtual Healthcare Conference
From Vir Biotechnology, Inc.
Via GlobeNewswire
Biden Administration Launches $5B Program To Boost Development Of Pan-Coronavirus Vaccine, Treatments
The White House plans to devote $5 billion to develop effective treatments and vaccines against current and future Covid variants, a Department of Health and Human Services (HHS) spokesperson and a... 
Via Benzinga
7 Thrilling Biotech Stocks for Aggressive Investors to Buy
Amid the noise of the global markets recently, these speculative biotech stocks to buy might trade with a mind of their own. 
Via InvestorPlace
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information
Via Benzinga
Biotech Stocks And The SVB Collapse — Here's What We Know
The collapse of SVB will have a big impact on early-stage, venture-backed companies. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.